Novartis Pharmaceuticals UK Limited
Novartis Pharmaceuticals UK Limited, a prominent player in the global healthcare landscape, is headquartered in Great Britain. Established in 1996, the company has made significant strides in the pharmaceutical industry, focusing on innovative medicines and advanced therapies across various therapeutic areas, including oncology, cardiology, and immunology. With a commitment to research and development, Novartis is renowned for its unique portfolio of prescription medications and cutting-edge treatments that address unmet medical needs. The company has achieved notable milestones, including the launch of groundbreaking therapies that have transformed patient care. As a leader in the pharmaceutical sector, Novartis Pharmaceuticals UK Limited continues to enhance its market position through strategic partnerships and a robust pipeline of products, solidifying its reputation for excellence in healthcare innovation.
DitchCarbon Score
How does Novartis Pharmaceuticals UK Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novartis Pharmaceuticals UK Limited's score of 65 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novartis Pharmaceuticals UK Limited's reported carbon emissions
Novartis Pharmaceuticals UK Limited, headquartered in Great Britain, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or the scope of their emissions (Scope 1, 2, or 3). However, the company is likely engaged in various climate commitments and initiatives typical of the pharmaceutical industry, focusing on sustainability and reducing environmental impact. As the industry increasingly prioritises climate action, Novartis may be aligning its strategies with broader corporate sustainability goals. Further information on their specific commitments or initiatives would be necessary to provide a comprehensive overview of their climate efforts.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novartis Pharmaceuticals UK Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
